Statement: the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally. regimen used to treat malignant peritoneal neoplasm is any regimen that can be used for the treatment of malignant peritoneal  neoplasm.
Primary_evidence: INTERVENTION 1:    Fulvestrant + Everolimus   Fulvestrant + Everolimus   Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that.